Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Medidata Solutions Inc    MDSO

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Medidata Solutions Inc : Medidata Solutions Announces Two-for-One Stock Split

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/11/2013 | 12:31pm CEST

Medidata Solutions (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that its Board of Directors approved a two-for-one (2:1) split of the Company's common stock at a regularly scheduled board meeting on November 7, 2013. The stock split will be structured in the form of a stock dividend.

The record date for the stock split is December 2, 2013. Shareholders of record as of such date will receive one new share of common stock for each share that they own. The distribution of the new shares will be made on December 16, 2013, and trading on a split-adjusted basis is expected to begin on or about December 17, 2013.

Medidata had approximately 26.8 million shares of common stock outstanding as of November 7, 2013. The stock split will increase the common shares outstanding to approximately 53.6 million.

About Medidata Solutions

Medidata Solutions is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud TM brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of our global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations.

Investors:
Medidata Solutions
Hulus Alpay, 212-419-1025
halpay@mdsol.com
or
Media:
Medidata Solutions
Gail Janowitz, 212-918-1792
gjanowitz@mdsol.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDIDATA SOLUTIONS INC
08/17 MEDIDATA : Fosun Pharma Selects Medidata's Unified Platform for Clinical Develop..
08/17 MEDIDATA : Fosun Pharma Selects Medidata’s Unified Platform for Clinical D..
08/07 MEDIDATA : Earns Recognition as Leading Innovative Company and a Great Place to ..
08/01 MEDIDATA : Management's Discussion and Analysis of Financial Condition and Resul..
07/20 MEDIDATA : "Nature Reviews Drug Discovery" Publishes New Findings on Trial Compl..
07/20 MEDIDATA : “Nature Reviews Drug Discovery” Publishes New Findings on..
07/18 MEDIDATA SOLUTIONS, INC. (NASDAQ : MDSO) reported earnings of $0.31 per share be..
07/18 MEDIDATA : beats Street 2Q forecasts
07/18 MEDIDATA SOLUTIONS, INC. (NASDAQ : MDSO) Files An 8-K Results of Operations and ..
07/18 MEDIDATA SOLUTIONS, INC. : Results of Operations and Financial Condition, Financ..
More news
News from SeekingAlpha
07/30 iShares Brings You Small Cap By The Thousands
07/18 Medidata Solutions' (MDSO) CEO Tarek Sherif on Q2 2017 Results - Earnings Cal..
07/18 Veeva Systems sues Medidata, others over employee rights
07/18 Medidata Solutions beats by $0.03, beats on revenue
07/17 Notable earnings before Tuesday?s open
Financials ($)
Sales 2017 554 M
EBIT 2017 120 M
Net income 2017 37,0 M
Finance 2017 66,2 M
Yield 2017 -
P/E ratio 2017 112,28
P/E ratio 2018 85,11
EV / Sales 2017 7,52x
EV / Sales 2018 6,13x
Capitalization 4 232 M
Chart MEDIDATA SOLUTIONS INC
Duration : Period :
Medidata Solutions Inc Technical Analysis Chart | MDSO | US58471A1051 | 4-Traders
Technical analysis trends MEDIDATA SOLUTIONS INC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 87,2 $
Spread / Average Target 21%
EPS Revisions
Managers
NameTitle
Tarek A. Sherif Chairman & Chief Executive Officer
Glen Michael de Vries President & Director
Michael L. Capone Chief Operating Officer
Rouven Bergmann Chief Financial & Accounting Officer
Julie Iskow Chief Technology Officer
Sector and Competitors